 Antibody Affinity
"Antibody Affinity" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measure of the binding strength between antibody and a simple hapten or antigen determinant. It depends on the closeness of stereochemical fit between antibody combining sites and antigen determinants, on the size of the area of contact between them, and on the distribution of charged and hydrophobic groups. It includes the concept of "avidity," which refers to the strength of the antigen-antibody bond after formation of reversible complexes.
| Descriptor ID |
D000915
|
| MeSH Number(s) |
G12.040 G12.122.125
|
| Concept/Terms |
Antibody Affinity- Antibody Affinity
- Affinity, Antibody
- Affinities, Antibody
- Antibody Affinities
Antibody Avidity- Antibody Avidity
- Antibody Avidities
- Avidities, Antibody
- Avidity, Antibody
|
Below are MeSH descriptors whose meaning is more general than "Antibody Affinity".
Below are MeSH descriptors whose meaning is more specific than "Antibody Affinity".
This graph shows the total number of publications written about "Antibody Affinity" by people in this website by year, and whether "Antibody Affinity" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 1999 | 0 | 1 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 1 | 1 | 2 | | 2006 | 0 | 1 | 1 | | 2007 | 0 | 2 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 1 | 2 | 3 | | 2011 | 0 | 1 | 1 | | 2012 | 0 | 1 | 1 | | 2013 | 0 | 1 | 1 | | 2014 | 1 | 0 | 1 | | 2016 | 0 | 1 | 1 | | 2017 | 0 | 1 | 1 | | 2018 | 0 | 2 | 2 | | 2019 | 1 | 0 | 1 | | 2020 | 1 | 2 | 3 | | 2021 | 0 | 2 | 2 | | 2024 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Antibody Affinity" by people in Profiles.
-
Whitehead TA. Deep screening of antibody-antigen affinities. Nat Biomed Eng. 2024 Mar; 8(3):203-204.
-
Schmid DS, Miao C, Leung J, Johnson M, Weinberg A, Levin MJ. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines. J Virol. 2021 05 24; 95(12).
-
Freyn AW, Han J, Guthmiller JJ, Bailey MJ, Neu K, Turner HL, Rosado VC, Chromikova V, Huang M, Strohmeier S, Liu STH, Simon V, Krammer F, Ward AB, Palese P, Wilson PC, Nachbagauer R. Influenza hemagglutinin-specific IgA Fc-effector functionality is restricted to stalk epitopes. Proc Natl Acad Sci U S A. 2021 02 23; 118(8).
-
Boughter CT, Borowska MT, Guthmiller JJ, Bendelac A, Wilson PC, Roux B, Adams EJ. Biochemical patterns of antibody polyreactivity revealed through a bioinformatics-based analysis of CDR loops. Elife. 2020 11 10; 9.
-
Guthmiller JJ, Lan LY, Fern?ndez-Quintero ML, Han J, Utset HA, Bitar DJ, Hamel NJ, Stovicek O, Li L, Tepora M, Henry C, Neu KE, Dugan HL, Borowska MT, Chen YQ, Liu STH, Stamper CT, Zheng NY, Huang M, Palm AE, Garc?a-Sastre A, Nachbagauer R, Palese P, Coughlan L, Krammer F, Ward AB, Liedl KR, Wilson PC. Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza Viruses. Immunity. 2020 12 15; 53(6):1230-1244.e5.
-
Kimuda SG, Andia-Biraro I, Sebina I, Egesa M, Nalwoga A, Smith SG, Bagaya BS, Levin J, Elliott AM, Raynes JG, Cose S. Mycobacterium tuberculosis infection is associated with increased B cell responses to unrelated pathogens. Sci Rep. 2020 08 31; 10(1):14324.
-
Cepeda JR, Sekhar NS, Han J, Xiong W, Zhang N, Yu L, Dai S, Davidson HW, Kappler JW, An Z, Zhang L. A monoclonal antibody with broad specificity for the ligands of insulin B:9-23 reactive T cells prevents spontaneous type 1 diabetes in mice. MAbs. 2020 Jan-Dec; 12(1):1836714.
-
Duan T, Tradtrantip L, Phuan PW, Bennett JL, Verkman AS. Affinity-matured 'aquaporumab' anti-aquaporin-4 antibody for therapy of seropositive neuromyelitis optica spectrum disorders. Neuropharmacology. 2020 01 01; 162:107827.
-
Su Y, Liu Y, Behrens CR, Bidlingmaier S, Lee NK, Aggarwal R, Sherbenou DW, Burlingame AL, Hann BC, Simko JP, Premasekharan G, Paris PL, Shuman MA, Seo Y, Small EJ, Liu B. Targeting CD46 for both adenocarcinoma and neuroendocrine prostate cancer. JCI Insight. 2018 09 06; 3(17).
-
Fenstermaker RA, Figel SA, Qiu J, Barone TA, Dharma SS, Winograd EK, Galbo PM, Wiltsie LM, Ciesielski MJ. Survivin Monoclonal Antibodies Detect Survivin Cell Surface Expression and Inhibit Tumor Growth In Vivo. Clin Cancer Res. 2018 06 01; 24(11):2642-2652.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|